Parag Roy, Medical Oncologist at Tata Main Hospital shared a post on LinkedIn:
“Practice-changing data in relapsed/refractory multiple myeloma.
The phase 3 MajesTEC-3 trial (NEJM, Feb 19, 2026) delivers striking results for patients with 1-3 prior lines of therapy.
Study design.
Teclistamab (BCMA bispecific T-cell engager) + subcutaneous daratumumab vs standard daratumumab-based regimens (DPd or DVd).
Key efficacy outcomes (median follow-up ~34.5 months):
- 36-mo PFS: 83.4% vs 29.7%.
- HR 0.17 → ~83% reduction in risk of progression/death.
- ≥CR: 81.8% vs 32.1%.
- ORR: 89.0% vs 75.3%.
- MRD negativity: 58.4% vs 17.1%.
Safety:
- Serious AEs: 70.7% vs 62.4%.
- Treatment-related deaths: 7.1% vs 5.9%.
Clinical takeaways:
- Moves BCMA bispecific therapy earlier in the relapse setting.
- Delivers unprecedented depth of response for this line.
- Reinforces the power of off-the-shelf immunotherapy combinations.
If durability holds with longer follow-up, this regimen has strong potential to redefine the standard of care after first relapse.
Curious how colleagues are thinking about sequencing vs CAR-T and other BCMA-directed approaches in this space.”
Other articles about Myeloma on OncoDaily.